

**LEMBAR
HASIL PENILAIAN SEJAWAT SEBIDANG ATAU PEER REVIEW
KARYA ILMIAH : JURNAL ILMIAH**

Judul Karya Ilmiah (Artikel) : BRCA1 Gene Mutation Screening for the Hereditary Breast and/or Ovarian Cancer Syndrome in Breast Cancer Cases: a First High Resolution DNA Melting Analysis in Indonesia

Jumlah Penulis : 4 Orang

Status Pengusul : Farmaditya EP Mundhofir, Catharina Endah Wulandari, Yan Wisnu Prajoko, Tri Indah Winarni

Identitas Jurnal Ilmiah :

- a. Nama Jurnal : Asian Pacific Journal of Cancer Prevention
- b. Nomor ISSN : 15137368
- c. Vol, Nomor, halaman : 7 (3), p:1539-1546
- d. Edisi : 2016
- e. Penerbit : West Asia Organization for Cancer Prevention (WAOCOP)
- g. DOI artikel (jika ada):<http://dx.doi.org/10.7314/APJCP.2016.17.3.1539>
- h. Alamat web jurnal : http://journal.waocp.org/article_32275_8cda3d03a0e7db7c5f2b66db15c23290.pdf/
- i. Terindeks di : Q2 SJR 0,5, H Index 70
- j. On line turnitin :

https://doc-pak.undip.ac.id/4824/1/TURNITIN_BRCA1_Gene_Mutation_Screening.pdf

Kategori Publikasi Jurnal Ilmiah : Jurnal Ilmiah Internasional/ Internasional Bereputasi**
 Jurnal Ilmiah Nasional Terakreditasi
 Jurnal Ilmiah Nasional/Nasional

Hasil Penilaian Peer Review :

Komponen Yang Dinilai	Nilai Maksimal Jurnal Ilmiah			Nilai Akhir Yang Diperoleh
	Internasional / Internasional Bereputasi ** 40	Nasional Terakreditasi	Nasional ***	
a. Kelengkapan unsur isi artikel (10%)	4			4
b. Ruang lingkup dan kedalaman pembahasan (30%)	12			11
c. Kecukupan dan kemutahiran data/informasi dan metodologi (30%)	12			11
d. Kelengkapan unsur dan kualitas terbitan/jurnal (30%)	12			12
Total = (100%)	40			38
Nilai Pengusul =				40% x 38/3 = 5,06

Catatan penilaian Artikel oleh Reviewer :

- a. **Kelengkapan unsur isi artikel** : Unsur artikel sudah lengkap abstrak, pendahuluan, metode, hasil dan pembahasan sudah dijelaskan dengan baik. Abstrak kurang terstruktur tetapi cukup jelas dalam menggambarkan penelitian secara garis besar
- b. **Ruang lingkup dan kedalaman pembahasan** : Ruang lingkup sesuai pengusul (Bedah onkologi) dalam menskrining gen dari penderita breast cancer
- c. **Kecukupan dan kemutahiran data/informasi dan metodologi**: Data dikumpulkan dengan menggunakan sekuensing gen sehingga dapat dianggap sebagai metode yang baik dan akurat
- d. **Kelengkapan unsur dan kualitas terbitan/ jurnal**: Jurnal internasional terindex Scopus Q2, SJR > 0,1

Semarang,
Reviewer 1

Prof. Dr. dr. Tri Nur Kristina, DMM, M.Kes
NIP. 19590527 198603 2 001
Bidang kerja : Fakultas Kedokteran Undip
Unit ilmu : Ilmu Kedokteran
Jabatan pangkat : Guru Besar

**LEMBAR
HASIL PENILAIAN SEJAWAT SEBIDANG ATAU PEER REVIEW
KARYA ILMIAH : JURNAL ILMIAH**

Judul Karya Ilmiah (Artikel) : BRCA1 Gene Mutation Screening for the Hereditary Breast and/or Ovarian Cancer Syndrome in Breast Cancer Cases: a First High Resolution DNA Melting Analysis in Indonesia

Jurulah Penulis : 4 Orang

Status Pengusul : Farmaditya EP Mundhofir, Catharina Endah Wulandari, Yan WisnuPrajoko, Tri Indah Winarni

Identitas Jurnal Ilmiah :

- a. Nama Jurnal : Asian Pacific Journal of Cancer Prevention
- b. Nomor ISSN : 15137368
- c. Vol, Nomor, halaman: 7 (3), p:1539-1546
- d. Edisi : 2016
- e. Penerbit : West Asia Organization for Cancer Prevention (WAOCOP)
- g. DOI artikel (jika ada):<http://dx.doi.org/10.7314/APJCP.2016.17.3.1539>
- h. Alamat web jurnal : http://journal.waocp.org/article_32275_8cda3d03a0e7db7c5f2b66db15c23290.pdf/
- i. Terindeks di : Q2 SJR 0,5, H Index 70
- j. On line turnitin :

https://doc-pak.undip.ac.id/4824/1/TURNITIN_BRCA1_Gene_Mutation_Screening.pdf

Kategori Publikasi Jurnal Ilmiah : **Jurnal Ilmiah Internasional/ Internasional Bereputasi****
 (beri ✓ pada kategori yang tepat) Jurnal Ilmiah Nasional Terakreditasi
 Jurnal Ilmiah Nasional/Nasional

Hasil Penilaian Peer Review :

Komponen Yang Dinilai	Nilai Maksimal Jurnal Ilmiah			Nilai Akhir Yang Diperoleh
	Internasional / Internasional Bereputasi ** 40	Nasional Terakreditasi	Nasional ***	
a. Kelengkapan unsur isi artikel (10%)	2			2,0
b. Ruang lingkup dan kedalaman pembahasan (30%)	12			12,0
c. Kecukupan dan kemutahiran data/informasi dan metodologi (30%)	12			12,0
d. Kelengkapan unsur dan kualitas terbitan/ jurnal (30%)	12			12,0
Total = (100%)	40			40,0
Nilai Pengusul =				40% x 40,0 / 3 = 5,33

Catatan penilaian Artikel oleh Reviewer :

- a. Kelengkapan unsur isi artikel : unsur isi artikel lengkap, hanya pada abstrak tidak tercantum tujuan penelitian, tujuan jelas pada pendahuluan, sistematika dan cara penulisan sesuai kaidah penulisan ilmiah, metode diuraikan secara rinci, dijelaskan pula tentang etika penelitian, hasil dan diskusi didukung pustaka yang baru dan relevan
- b. Ruang lingkup dan kedalaman pembahasan : lingkup penelitian sesuai dengan bidang ilmu pengusul sebagai seorang ahli bedah onkologi. Hasilnya dibahas secara luas, tampak kemanfaatan penelitian dan hasilnya juga dibandingkan dengan mensitasi hasil penelitian terdahulu, dengan pustaka yang baru dan relevan
- c. Kecukupan dan kemutahiran data/informasi dan metodologi: studi populasi, data didapat dari 100 responden pasien kanker payudara, dilakukan interview tentang tanda dan gejala klinis, riwayat keluarga dll tentang kanker, data dinilai dan dianalisis dengan skoring BOADICEA yang terstandar
- d. Kelengkapan unsur dan kualitas terbitan/ jurnal:
 Asian Pasific Journal of Cancer Prevention adalah Jurnal internasional terindeks scopus Q2, SJR 0,5 dan H indeks 70, diterbitkan oleh West Asia Organization for Cancer Prevention

Semarang, 13 Februari 2021

Reviewer 1

Prof. Dr. drg. Oedijani, M.S.

NIP. 194902091979012001

Bidang ilmu : Fakultas Kedokteran Undip

Unit kerja : Ilmu Kedokteran

Jabatan pangkat : Guru Besar



< Back to results | < Previous 18 of 28 Next >

[Export](#) [Download](#) [Print](#) [E-mail](#) [Save to PDF](#) [Save to list](#) [More... >](#)
[View at Publisher](#)**Document type**

Article

Source type

Journal

ISSN

15137368

DOI

10.7314/APJCP.2016.17.3.1539

[View more](#) ▾[Asian Pacific Journal of Cancer Prevention](#) • Open Access • Volume 17, Issue 3, Pages 1539 - 1546 • 19 April 2016

BRCA1 gene mutation screening for the Hereditary Breast and/or Ovarian cancer syndrome in breast cancer cases: A first high resolution DNA melting analysis in Indonesia

Mundhofir F.E.P.^a , Wulandari C.E.^a, Prajoko Y.W.^b, Winarni T.I.^a[Save all to author list](#)^a Division of Human Genetics, Faculty of Medicine, Center for Biomedical Research (CEBIOR), Diponegoro University, Semarang, Indonesia^b Division of Oncology Surgery, Department of Surgery, Faculty of Medicine, Diponegoro University, Dr. Kariadi Hospital, Semarang, Indonesia

2

Citations in Scopus

20

Views count

[View all metrics >](#)**Abstract****Author keywords****Indexed keywords****SciVal Topics****Chemicals and CAS Registry Numbers****Metrics****Funding details****Abstract**

Specific patterns of the hereditary breast and ovarian cancer (HBOC) syndrome are related to mutations in the BRCA1 gene. One hundred unrelated breast cancer patients were interviewed to obtain clinical symptoms and signs, pedigree and familial history of HBOC syndrome related cancer. Subsequently, data were calculated using the Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA) risk prediction model. Patients with high score of BOADICEA were offered genetic testing. Eleven patients with high score of BOADICEA, 2 patients with low score of BOADICEA, 2 patient's family members and 15 controls underwent BRCA1 genetic testing. Mutation screening using PCR-HRM was

Cited by 2 documents

A novel mutation-BRCA1 associated hereditary haplotype of intragenic markers of BRCA1 gene in a family with history of breast cancer

Miresmaeli, S.M. , Jafari, F. (2019) *Asian Pacific Journal of Cancer Prevention*

Mutations analysis of BRCA1 gene in patients with breast cancer in South Khorasan province, East Iran

Khalili-Tanha, G. , Sebzari, A. , Moodi, M. (2019) *Medical Journal of the Islamic Republic of Iran*

[View all 2 citing documents](#)

Inform me when this document is cited in Scopus:

[Set citation alert >](#)**Related documents**

Comparison of breast cancer in Indonesia and Malaysia - A clinicopathological study between dharmais cancer centre Jakarta and university Malaya medical centre, Kuala Lumpur

Ng, C.H. , Bhoo Pathy, N. , Taib, N.A. (2011) *Asian Pacific Journal of Cancer Prevention*

BRCA1 and BRCA2 common mutations in Iranian breast cancer patients: A meta analysis

Forat-Yazdi, M. , Neamatzadeh, H. , Sheikhh, M.H. (2015) *Asian Pacific Journal of Cancer Prevention*

Novel and reported pathogenic variants in exon 11 of BRCA2 gene in a cohort of Sri Lankan young breast cancer patients

De Silva, S. , Tennekoone, K.H. , Dissanayake, A. (2017) *Familial Cancer*

[View all related documents based on references](#)

Find more related documents in Scopus based on:

[Authors >](#) [Keywords >](#)

carried out in 22 exons (41 amplicons) of BRCA1 gene. Sanger sequencing was subjected in all samples with aberrant graph. This study identified 10 variants in the BRCA1 gene, consisting of 6 missense mutations (c.1480C>A, c.2612C>T, c.2566T>C, c.3113A>G, c.3548 A>G, c.4837 A>G), 3 synonymous mutations (c.2082 C>T, c.2311 T>C and c.4308T>C) and one intronic mutation (c.134+35 G>T). All variants tend to be polymorphisms and unclassified variants. However, no known pathogenic mutations were found.

Author keywords

BOADICEA; BRCA1 gene; HBOC syndrome; Indonesian population; PCR-HRM

Indexed keywords

SciVal Topics 

Chemicals and CAS Registry Numbers

Metrics

Funding details

References (43)

[View in search results format >](#)

All

[Export](#) [Print](#) [E-mail](#) [Save to PDF](#) [Create bibliography](#)

- 1 Akilzhanova, A., Nyshanbekkyzy, N., Nurkina, Z.
BRCA1 and BRCA2 gene mutations screening in sporadic breast cancer patients
In Kazakhstan
(2013) *Central Asian J Global Health*, 2, p. 29. Cited 2 times.

- 2 Aziz, M.F.
[Gynecological cancer in Indonesia \(Open Access\)](#)

(2009) *Journal of Gynecologic Oncology*, 20 (1), pp. 8-10. Cited 41 times.
doi: 10.3802/jgo.2009.20.1.8

[View at Publisher](#)

- 3 Hussein, A., Khoury, K.E., Dbouk, H., Khalil, L.E., Mouhieddine, T.H., El Saghir, N.S.
[Epidemiology and prognosis of breast cancer in young women](#)

(2013) *Journal of Thoracic Disease*, 5 (SUPPL.1), pp. S2-S8. Cited 192 times.
<http://www.jthoracdis.com/article/download/1215/1843>
doi: 10.3978/j.issn.2072-1439.2013.04.13

[View at Publisher](#)

- 4 Beaber, E.F., Buist, D.S.M., Barlow, W.E., Malone, K.E., Reed, S.D., Li, C.I.
[Recent oral contraceptive use by formulation and breast cancer risk among women 20 to 49 years of age \(Open Access\)](#)

(2014) *Cancer Research*, 74 (15), pp. 4078-4089. Cited 59 times.
<http://cancerres.aacrjournals.org/content/74/15/4078.full.pdf+html>
doi: 10.1158/0008-5472.CAN-13-3400

[View at Publisher](#)

- 40 Wahidin, M., Noviani, R., Hermawan, S., Andriani, V., Ardian, A., Djarir, H.
Population-based cancer registration in indonesia ([Open Access](#))
(2012) *Asian Pacific Journal of Cancer Prevention*, 13 (4), pp. 1709-1710. Cited 37 times.
http://www.apccontrol.org/paper_file/issue_abs/Volume13_No4/1709-10%202.20%20Wahidin.pdf
doi: 10.7314/APJCP.2012.13.4.1709

[View at Publisher](#)

-
- 41 Yip, C.-H.
Breast cancer in Asia
(2009) *Methods in Molecular Biology*, 471, pp. 51-64. Cited 52 times.
ISBN: 978-158829987-1
doi: 10.1007/978-1-59745-416-2_3

[View at Publisher](#)

-
- 42 Yip, C.-H., Cazap, E., Anderson, B.O., Bright, K.L., Caleffi, M., Cardoso, F., Elzawawy, A.M., (...), Khaled, H.M.
Breast cancer management in middle-resource countries (MRCs): Consensus statement from the Breast Health Global Initiative ([Open Access](#))
(2011) *Breast*, 20 (SUPPL. 2), pp. S12-S19. Cited 50 times.
<http://www.elsevier-international.com/journals;brst/>
doi: 10.1016/j.breast.2011.02.015

[View at Publisher](#)

-
- 43 Youlden, D.R., Cramb, S.M., Yip, C.H., Baade, P.D.
Incidence and mortality of female breast cancer in the Asia-Pacific region
(2014) *Cancer Biology and Medicine*, 11 (2), pp. 101-115. Cited 244 times.
www.cancerbiomed.org
doi: 10.7497/j.issn.2095-3941.2014.02.005

[View at Publisher](#)

✉ Mundhofir, F.E.P.; Division of Human Genetics, Faculty of Medicine, Center for Biomedical Research (CEBIOR), Diponegoro University, Semarang, Indonesia;
email:farmaditya@yahoo.com
© Copyright 2018 Elsevier B.V., All rights reserved.

[< Back to results](#) | [< Previous](#) 18 of 28 [Next >](#)

[^ Top of page](#)

About Scopus

- [What is Scopus](#)
- [Content coverage](#)
- [Scopus blog](#)
- [Scopus API](#)
- [Privacy matters](#)

Language

- [日本語に切り替える](#)
- [切换到简体中文](#)
- [切换到繁體中文](#)
- [Русский язык](#)

Customer Service

- [Help](#)
- [Contact us](#)


ELSEVIER

[Terms and conditions ↗](#) [Privacy policy ↗](#)

Copyright © Elsevier B.V. All rights reserved. Scopus® is a registered trademark of Elsevier B.V.

We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

 RELX



Honorary Editor-in-Chief

 **Malcolm Anthony Moore, Ph.D.**

Toxicologist

📍 *Director-Coordination, Asia Pacific Organization for
Cancer Prevention, Korean Cancer Center, Goyang,
Korea.*

✉ apocpcontrol@gmail.com

Associate Editor

 **Prof. David Roder**

Professor of Cancer Epidemiology

📍 *Chair Cancer Epidemiology and Population Health,
Beat Cancer Project, University of South Australia,
Adelaide, Australia*

🌐 ca.linkedin.com/in/david-roder-54699329
✉ roder@internode.on.net

 More

 **Dr. Abhishek Shankar**

Preventive Oncology, Radiation Oncology

📍 *Assistant Professor*

Department of Preventive Oncology,

Dr B R Ambedkar Instituite Rotary Cancer Hospital

All India Institute of Medical Sciences,

Delhi, India

✉ doc.abhishankar@gmail.com

✚ More

Founder **Yip Cheng-Har, MD, FACS**

Surgery

📍 *Prof. of Gynaecological Oncology*

Faculty of Medicine, University Tunku Abdul Rahman,

Kuala Lumpur, Malaysaa

✉ chenghar.yip@gmail.com

✚ More

 **Keun-Young Yoo, MD, Ph.D.**

Prof. of Cancer Epidemiology

 *President, APOCP*

President, Armed Forces Capital Hospital

*Professor, Seoul National University College of
Medicine, Seoul, Korea*

 bkkyoo@gmail.com

 **More**

 **Kazuo Tajima, MD**

Pathology

 *Prof. of Pathology*

*Director, Aichi Cancer Center Research Institute, Ozaka,
Japan*

 ktajima@clin.medic.mie-u.ac.jp

 **More**

👤 Prof. You Lin Qiao, M.D. Ph.D.,

Epidemiology

📍 *Director, Dept. of Cancer Epidemiology
Cancer Hospital, Chinese Academy of Medical Sciences
& Peking Union Medical College
Beijing, China*
✉ qiaoy@cicams.ac.cn

International Advisory Board

👤 Dr. Khuseynov Zafardzhon

Oncologist

📍 *Director of the Republic Oncological Scientific Center,
Ministry of public health, Republic of Tajikistan*
✉ zafhab@mail.ru
☎ +992907710535

 **Prof. Niveen Abu-Rmeileh**

Community Medicine

📍 Associate prof. of Community Medicine
*Institute of Community and Public Health,
Birzeit University,
Birzeit – Palestine*

✉ nrmeileh@gmail.com

⊕ More

 **Prof. Rema Gvamichava**

Prof. of Surgery

📍 A. Gvamichava National Cancer Center,
*Tbilisi State Medical University
Tbilisi, Georgia*

✉ doctorrema@yahoo.com

Volume & Issue: Volume 17, Issue 3, March 2016 **1. Microchips and their Significance in Isolation of Circulating Tumor Cells and Monitoring of Cancers**

Pages 879-894

Mehdi Sahmani; Mousa Vatanmakanian; Mehdi Goudarzi; Naser Mobarra; Mehdi Azad

View Article  PDF 742.22 K**2. Preventive and Risk Reduction Strategies for Women at High Risk of Developing Breast Cancer: a Review**

Pages 895-904

Arvind Krishnamurthy; Viveka Soundara; Vijayalakshmi Ramshankar

View Article  PDF 454.84 K**3. Immune Checkpoint Inhibitors: Therapeutic Tools for Breast Cancer**

Pages 905-910

Min Su; Chun-Xia Huang; Ai-Ping Dai

View Article  PDF 471.45 K**4. Leukemic Oral Manifestations and their Management**

Pages 911-915

Carolina Favaro Francisconi; Rogerio Jardim Caldas; Lazara Joyce Oliveira Martins; Cassia Maria Fischer Rubira; Paulo Sergio da Silva Santos

View Article  PDF 366.91 K**5. Helicobacter pylori Infection and Dietary Factors Act Synergistically to Promote Gastric Cancer**

Pages 917-921

Negin Raei; Bahador Behrouz; Saber Zahri; Saeid Latifi-Navid

View Article  PDF 410.47 K**6. Coexisting JAK2V617F and CALR Exon 9 Mutations in Myeloproliferative Neoplasms - Do They Designate a New Subtype?**

Pages 923-926

Rifat Zubair Ahmed; Munazza Rashid; Nuzhat Ahmed; Muhammad Nadeem; Tahir Sultan Shamsi

View Article  PDF 401.41 K

93. Missing Elements in Surgical Pathology Reports: Breast, Colon and Stomach Cancers

Pages 1469-1472

Maryam Kadivar; Parnian Kheirkhah Rahimabad

[View Article](#)  PDF 408.65 K

94. Prevalence of Cigarette Smoking and Associated Factors among Male Citizens in Tehran, Iran

Pages 1473-1478

Aziz Kassani; Abdolvahab Baghbanian; Rostam Menati; Jafar Hassanzadeh; Mohsen Asadi-Lari; Walieh Menati

[View Article](#)  PDF 486.86 K

95. Determination of Patient Learning Needs after Thyroidectomy

Pages 1479-1483

Zeynep Temiz; Didem Ozturk; Gulay Altun Ugras; Seher Deniz Oztekin; Emel Sengul

[View Article](#)  PDF 442.11 K

96. Frequency of Cholelithiasis and Biliary Pathology in the Easter Island Rapanui and Non-Rapanui Populations

Pages 1485-1488

Eduardo Bravo; Jorge Contardo; Jerson Cea

[View Article](#)  PDF 337.4 K

97. Association of Serum HE4 with Primary Tumor Diameter and Depth of Myometrial Invasion in Endometrial Cancer Patients at Rajavithi Hospital

Pages 1489-1492

Nisa Prueksaritanond; Patchara Cheanpracha; Marut Yanaranop

[View Article](#)  PDF 482.62 K

98. Breast Cancer Trend in Iran from 2000 to 2009 and Prediction till 2020 using a Trend Analysis Method

Pages 1493-1498

Bibihajar Zahmatkesh; Afsaneh Keramat; Nasrinossadat Alavi; Ahmad Khosravi; Ahmad Kousha; Ali Ghanbari Motlagh; Mahboobeh Darman; Elham Partovipour; Reza Chaman

[View Article](#)  PDF 510.77 K



99. Molecular Mechanism of Crocin Induced Caspase Mediated MCF-7 Cell Death: In Vivo Toxicity Profiling and Ex Vivo Macrophage Activation

Pages 1499-1506

Hamid A Bakshi; Faruck Lukmanul Hakkim; Smitha Sam

[View Article](#)  PDF 1.41 MB**100. Hormone Use is Associated with Lymphovascular Invasion in Breast Cancer**

Pages 1507-1512

Margaretha Loof-Johanson; Lars Brudin; Marie Sundquist; Carl Edvard Rudebeck

[View Article](#)  PDF 467.32 K**101. Phase III of Study of R-CHOP-21 vs R-CHOP-14 for Untreated Stage III and IV B-cell Non-Hodgkin's Lymphoma: a Report from Iran**

Pages 1513-1517

Mehrdad Payandeh; Safa Najafi; Fateme-Zahra Shojaian; Masoud Sadeghi

[View Article](#)  PDF 534.15 K**102. Secretion and Expression of Matrix Metalloproteinase-2 and 9 from Bone Marrow Mononuclear Cells in Myelodysplastic Syndrome and Acute Myeloid Leukemia**

Pages 1519-1529

Ajay K Chaudhary; Shruti Chaudhary; Kanjaksha Ghosh; Chandrakala Shanmukaiah; Anita H Nadkarni

[View Article](#)  PDF 1.4 MB**103. Clinico-Epidemiological Profile of Patients with Polycythaemia Rubra Vera - a Five Year Experience from a Tertiary Care Center**

Pages 1531-1533

Sadia Sultan; Syed Mohammed Irfan; Sania Murad

[View Article](#)  PDF 341.91 K**104. Adult Primary Myelodysplastic Syndrome: Experience from a Tertiary Care Center in Pakistan**

Pages 1535-1537

Sadia Sultan; Syed Mohammed Irfan

[View Article](#)  PDF 332.84 K

105. BRCA1 Gene Mutation Screening for the Hereditary Breast and/or Ovarian Cancer Syndrome in Breast Cancer Cases: a First High Resolution DNA Melting Analysis in Indonesia

Pages 1539-1546

Farmaditya EP Mundhofir; Catharina Endah Wulandari; Yan Wisnu Prajoko; Tri Indah Winarni

[View Article](#)  PDF 603.56 K

106. Prognostic Factors and Survival in Acute Myeloid Leukemia Cases: a Report from the Northeast of Iran

Pages 1547-1551

Abolghasem Allahyari; Tarane Tajeri; Masoud Sadeghi

[View Article](#)  PDF 559.54 K

107. Arsenic Trioxide Induces Apoptosis and Incapacitates Proliferation and Invasive Properties of U87MG Glioblastoma Cells through a Possible NF-B-Mediated Mechanism

Pages 1553-1564

Seyed H Ghaffari; Meysam Yousefi; Majid Zaki Dizaji; Majid Momeny; Davood Bashash; Ali Zekri; Kamran Alimoghaddam; Ardeshir Ghavamzadeh

[View Article](#)  PDF 1.47 MB

108. Central, Extraventricular and Atypical Neurocytomas: a Clinicopathologic Study of 35 Cases from Pakistan Plus a Detailed Review of the Published Literature

Pages 1565-1570

Zubair Ahmad; Aisha Memon; Mohammad Usman Tariq; Romana Idrees; Sheema Hasan

[View Article](#)  PDF 1.04 MB

109. Pharmacological Analysis of Vorinostat Analogues as Potential Anti-tumor Agents Targeting Human Histone Deacetylases: an Epigenetic Treatment Stratagem for Cancers

Pages 1571-1576

Sugathan Praseetha; Srinivas Bandaru; Anuraj Nayarissery; Sivanpillai Sureshkumar

[View Article](#)  PDF 1.48 MB

110. Estimating the Burden of Cancers Attributable to Smoking Using Disability Adjusted Life Years in Indonesia

Pages 1577-1581

Susi Ari Kristina; Dwi Endarti; Natalia Sendjaya; Octy Pramestuty

[View Article](#)  PDF 452.04 K



111. The ICAM-1 Gly241Arg Polymorphism is Not Associated With Polycystic Ovary Syndrome - Results from a Case Control study in Kashmir, India

Pages 1583-1588

Syed Douhath Yousuf; Mohammad Ashraf Ganie; Mohammad Afzal Zargar; Tabasum Parvez; Fouzia Rashid

[View Article](#) [PDF 587.2 K](#)

112. Prevalence and Factors Associated with *Opisthorchis viverrini* Infection in Khammouane Province, Lao PDR

Pages 1589-1593

Khamphanavanh Saiyachak; Suttiporn Tongsotsang; Thitima Saenrueang; Malcolm A Moore; Supannee Promthet

[View Article](#) [PDF 405.82 K](#)

ISSN 1513-7368

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION




The Official Publication of the Asian Pacific Organization for Cancer Prevention and Control and the ICCC Asia Regional Office for Cancer Control
An Official Journal of the International Association of Cancer Registries



Volume 8, Number 1, 2008
Figures from UICC , pp. 1-6



UICC
Asian cancer control



APCTP Areas
 Australia
 Central Asia
 China
 Japan
 Korea

RESEARCH ARTICLE

Hormone Use is Associated with Lymphovascular Invasion in Breast Cancer

Margaretha Loof-Johanson^{1*}, Lars Brudin^{1,2}, Marie Sundquist³, Carl Edvard Rudebeck⁴

Abstract

Background: Risk of developing breast cancer increases with short breastfeeding and the use of hormones. The prognosis of breast cancer is better if the tumours are hormone receptor positive. Since breast feeding affects estrogen and progesterone receptors, we wanted to investigate how such reproductive factors as breastfeeding and the use of hormones interact with known prognostic markers and specific tumour characteristics in women with breast cancer. **Materials and Methods:** A total of 250 women treated for breast cancer from a larger cohort completed a questionnaire on breastfeeding, number and age at births and use of hormones. A logistic regression analysis was made to search for connections between known prognostic markers on the one hand (type of cancer, grade, tumor size, estrogen receptor and progesterone receptor, lymphovascular invasion and DNA-ploidy) and reproductive data, breastfeeding, and hormone use on the other. **Results and Conclusions:** Hormone use, but not breastfeeding, was significantly associated, also on multivariate analysis, with the prognostic variable lymphovascular invasion, connected to a worse prognosis. No other hormone use or breast feeding correlations with prognostic variables were found.

Keywords: Breastfeeding - childbirth - breast cancer - prognostic factors in breast cancer - LVI - NHG - DNA - ER/PR

Asian Pac J Cancer Prev, 17 (3), 1507-1512

Introduction

Risk of developing breast cancer increases with short breastfeeding and use of hormones (Collaborative Group on Hormonal Factors in Breast Cancer 2002; Anothaisintawee et al., 2013; Antoine et al., 2014; Schneider et al., 2014). Anothaisintawee et al., 2013 assumed that the etiology of breast cancer can be explained by two mechanisms of differentiation and proliferation of breast epithelial cells mediated by hormonal factors. They found associated adverse risk factors for both mechanisms in the use of oral contraceptives (OC) and hormonal replacement therapy (HRT). The association with breastfeeding as a significant and positive influence factor against breast cancer decreased the risk with 28% if breastfeeding ≥ 12 months.

Li et al. found, 2013 that breastfeeding generates a lower risk of triple-negative breast cancer, (TNBC=negative ER/PR and Her2 breast cancer) supported by both their case-control studies ($p=0.02$) and case-case comparisons ($p=0.01$). Their observations are consistent with the results of the majority of studies that have assessed these relationships and breastfeeding is the most consistently identified factor to be differentially associated with risk of triple-negative cancer compared to other major molecular

subtypes of the disease. The biological mechanisms for this is largely unknown.

Phipps et al., 2011, present different results. They found that nulliparity was associated with decreased risk of triple-negative breast cancer but increased risk of ER+ breast cancer. Among parous women, the number of births was positively associated with risk of triple-negative disease for three births or more vs one birth- and inversely associated with risk of ER+ disease. Ages at menarche and menopause were modestly associated with risk of ER+ but not triple-negative breast cancer; breastfeeding and oral contraceptive use were not associated with either subtype.

Work et al. assume, 2014, that the ER / PR negative breast cancer has a poorer prognosis compared with other subtypes of breast cancer and that breast-feeding > 12 months can reduce the risk of all subtypes and with the strongest effect on ER- / PR-.

Our knowledge of how reproductive factors and the use of hormones affect the risk of developing breast cancer is greater than our knowledge of how the prognosis of the breast cancer is affected. Here we have a large need for research (Kwan et al., 2015).

Our aim was to evaluate if reproductive factors or use of hormones were associated with any specific tumour characteristics. Since breast feeding and the use of

¹Department Medical and Health Sciences, University of Linkoping, ²Department of Clinical Physiology, ³Department of Surgery, County Hospital, Kalmar, Sweden, ⁴Department of Community Medicine, University of Tromso, Tromso, Norway *For correspondence: 0485.40311@telia.com

RESEARCH ARTICLE

Prognostic Factors and Survival in Acute Myeloid Leukemia Cases: a Report from the Northeast of Iran

Abolghasem Allahyari¹, Tarane Tajeri², Masoud Sadeghi^{3*}

Abstract

Background: Acute myeloid leukemia (AML) is a clonal hematopoietic disorder resulting from genetic alterations in normal hematopoietic stem cells. The aim of this study was to evaluate prognostic factors and survival of AML patients in the Northeast of Iran. **Materials and Methods:** This retrospective study covered 96 patients with AML referred to Emam Reza Hospital, Mashhad city, Iran, from 2009 to 2015. Age, sex, blood group, type of AML, fever, consumption of amphotericin B, cytogenetic forms and survival were analyzed. Also, WBC, hemoglobin and platelet levels were checked. Mean follow-up was 30.5 months (60.4% mortality). Survival was plotted by GraphPad Prism 5 with Log-rank test. **Results:** The mean age for all AML patients at diagnosis was 40.4 years (range, 17-77 years). Some 42.7% patients were aged <35 years and 40.6% were male. In all patients, 76% had fever and 50% consumed amphotericin. T(15;17)(q22;q21) had the most prevalence (37.7%) compared to other forms. Out of 92 patients, O+(30.4%) was the most common blood group and AML-M5 (28.3%) the most common subtype. There was a significant difference in survival based on WBC and consumption of amphotericin B ($P<0.05$). **Conclusions:** WBC level, fever and consumption of amphotericin B proved to be factors for survival of AML patients. The mean age for patients in Iran is lower than other areas in the World and also survival in this study was higher than in other studies.

Keywords: AML - survival - amphotericin B - WBC - northeastern Iran

Asian Pac J Cancer Prev, 17 (3), 1547-1551

Introduction

Acute myeloid leukemia (AML) in adults is the most common malignant myeloid disorder and this disease is a heterogeneous clonal disorder of hemopoietic (blood-forming) progenitor cells. The median age at diagnosis for patients with AML is 70 years (Estey and Döhner, 2006). The etiology of AML is not well understood (Strom et al., 2012). A number of factors have been reported as affecting the outcome of the disease such as age, White Blood Cell (WBC) count in diagnosis, time to achieve complete remission, abnormal karyotypes and cytogenetics (Ayrem lou et al., 2012). Cytogenetic analysis at the time of diagnosis is among the most important independent prognostic factors in patients with AML (Mrozek, 2008). The chromosomal abnormalities such as t(8;21)(q22;q22), t(16;16) (p13;q22), and t(15;17) (q22;q21) have a good prognosis (Mazloumi et al., 2012). The prognosis of elderly patients with AML is usually dismal, while the true survival of older patients not included in clinical trials is not known (Pulsoni et al., 2004). Advances in understanding of the pathophysiology of AML have not yet led to major improvements in overall survival of adults

with this disease (Stone et al., 2004). AML is divided into subgroups that are distinguished by the morphology of the leukemia cells, specific chromosomal abnormalities, gene rearrangement patterns, and different clinical courses and response to therapy (Douer, 2003). AML is subdivided based on morphologic criteria by the French-American-British (FAB) classification (Walter et al., 2013). FAB group has classified AML cases into eight subgroups (M0-M7) (Ziae, 2004). National and international studies have reported AML-M2 as the predominant FAB subtype of AML (Harani et al., 2005). More patients with AML are presented with fever (over 50%) (Hassan et al., 1993). Because of the increasing prevalence and changing microbiological spectrum of invasive fungal infections, some form of amphotericin B still provides dependable and broad spectrum therapeutic alternative (Hamill, 2013). Invasive fungal diseases cause morbidity and mortality in patients with AML (Girmenia et al., 2012). Amphotericin B associates with reducing of neutropenic fever in the majority of patients (Spitzer et al., 1989).

The aim of this study is to evaluate prognostic factors and affecting of them on survival in AML patients in the Northeast of Iran

¹Department of Internal Medicine, Imam Reza Hospital, Mashhad University of Medical Science, ²Islamic Azad University of Mashhad, Medicine Faculty, Mashhad, ³Cancer Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran

*For correspondence: Sadeghi_mbrc@yahoo.com